Heres the realistic timeline: Phase 3 trials (AMAZE program): - AMAZE 1 (obesity) started February 2026, enrolling ~1,150 participants - Primary completion estimated: June 2029 - Phase 3 in T2D also being planned following the ADA 2026 data US FDA approval (projected): Q4 2030 at the earliest (GlobalData estimate) EU EMA approval (projected): Q1 2031 at the earliest Bulgaria and Eastern Europe: Typically 612 months after EMA approval for market access, depending on national reimbursement negotiations
This hormone helps lower blood sugar by telling the pancreas to release insulin when needed
Compounded tirzepatide targets the same GLP-1 and GIP receptors as Mounjaro, triggering identical appetite suppression and metabolic effects
The information and opinions were considered valid by VF Securities, Inc
BPC-157, short for Body Protection Compound 157, is a synthetic peptide made up of 15 amino acids
TB-500 10mg Summary Description: TB-500 is a synthetic heptapeptide analog of the actin-binding motif of thymosin ?4 (T?4), composed of the acetylated sequence Ac-LKKTETQ